ERBB2 and breast cancer: As shown in Table 3, SGLT1 and HER2+ status still retained their power to predict shorter DFS (p = 0.001 and p < 0.001, respectively) and OS (p = 0.002 and p < 0.001, respectively) in breast cancer patients.